Leukemia and Lymphoma Society: FDA Approves Drug Designed to Target Specific Mutation in Rare Blood Cancer Type
November 07, 2023
November 07, 2023
RYE BROOK, New York, Nov. 7 -- The Leukemia and Lymphoma Society issued the following news release:
* * *
The Leukemia & Lymphoma Society has provided funding to research that identified novel ways to attack the IDH mutation in patients with blood cancers.
The U.S. Food and Drug Administration (FDA) recently approved ivosidenib (Tibsovo(R)) for use in certain adults with myelodysplastic syndromes (MDS), which are a rare form of blood cancers.
* * *
The Leukemia & Lymphoma Society has provided funding to research that identified novel ways to attack the IDH mutation in patients with blood cancers.
The U.S. Food and Drug Administration (FDA) recently approved ivosidenib (Tibsovo(R)) for use in certain adults with myelodysplastic syndromes (MDS), which are a rare form of blood cancers.